# ZTS earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/ZTS) · [Earnings tab](https://www.lopjlb.com/stock/ZTS?tab=earnings)

Updated: 2026-08-06T05:49:37

Quarters analyzed: 8

## Cross-quarter narrative

Across eight quarterly CallCards, Zoetis moved from a period of double‑digit organic revenue growth and upbeat guidance (Q2‑Q4 2024) to a phase of modest or flat growth and increasingly cautious outlooks (2025‑2026). Early calls highlighted strong demand for Librela, Simparica Trio and dermatology products, a $6 billion share‑repurchase program, and a Medicated Feed Additive (MFA) divestiture that was on‑track and later delivered. By Q1 2025 the company flagged tariff exposure and slower Librela uptake, while competition in dermatology and triple‑combination parasiticides became a recurring theme. Subsequent quarters saw guidance trimmed repeatedly, pricing pressure and higher manufacturing costs noted, and new pipeline milestones (avian‑influenza vaccine, long‑acting Cytopoint, OA‑pain antibody) introduced. China headwinds, inventory dynamics and FX headwinds appeared early but faded from later commentary. The most persistent concerns are competitive pressure, pricing pressure, and macro‑tariff risk, whereas earlier fears around China and MFA impact have largely resolved. Overall the narrative shifts from rapid growth and confidence in franchise expansion to a more defensive stance focused on cost management, pipeline execution, and navigating a crowded competitive landscape.

## Latest CallCard · Q1

Zoetis Q1 2026 organic revenue flat as US companion animal declined 8% amid price-sensitive pet owners, clinic traffic drops, and intensified competition without market expansion; livestock +12% and international +10% offset; guidance lowered to 2-5% organic growth with cost program launched.','tone

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2026 Q1:** Zoetis Q1 2026 organic revenue flat as US companion animal declined 8% amid price-sensitive pet owners, clinic traffic drops, and intensified competition without market expansion; livestock +12% and international +10% offset; guidance lowered to 2-5% organic growth with cost program launched.','tone
- **2025 Q4:** Zoetis delivered 6% organic revenue growth in 2025, guided 3-5% for 2026 amid US macro pressure, competitive launches, and ERP transition causing one-time Q4 pull-forward.','tone': {'mgmt': 0.3, 'mgmt_rationale': 'Management highlighted durable portfolio, pipeline, and global footprint while acknowl
- **2025 Q3:** ZTS Q3: 4% organic revenue growth, 9% adj NI growth; guidance narrowed to 5.5-6.5% revenue, 5.5-7% earnings; Librela declining but stabilizing; Livestock strong; pipeline on track.','tone': {'mgmt': 0.2, 'mgmt_rationale': 'Management emphasizes resilient growth engine, strong pipeline execution, and
- **2025 Q2:** Zoetis posted 8% organic revenue growth, raised full‑year guidance and highlighted strong franchise performance, while noting slower Librela adoption and upcoming competitive pressures.
- **2025 Q1:** Zoetis Q1 2025: 9% organic revenue growth, maintains 6-8% full-year revenue guidance, lowers adj. net income guidance to 5-7% on enacted tariffs; strong Simparica, dermatology, OA pain growth; Librela adoption slower but long-term confidence; tariff exposure mainly from China APIs, mitigated by US m
- **2024 Q4:** Zoetis posted 11% operational revenue growth in 2024, highlighted strong Simparica, OA pain and dermatology franchises, and guided 6‑8% organic growth for 2025 while noting competition, FX headwinds and margin benefits from the MFA divestiture.
- **2024 Q3:** Zoetis posted 14% operational revenue growth in Q3, driven by strong Librela and Simparica Trio performance, raised full‑year guidance and highlighted a disciplined focus on high‑growth franchises while navigating MFA divestiture and China headwinds.
- **2024 Q2:** Zoetis Q2 2024: revenue +11% op, adj NI +18% op; Librela +142%, derm +18%, Simparica +22%; raised FY24 guidance to 9-11% op revenue growth, 13.5-15.5% op adj NI growth; $6B buyback approved. Medicated feed additives divestiture on track for H2 close. China headwinds persist. FDA label discussions fo

## Theme arcs

- **Revenue growth trajectory** (deteriorating): Organic growth fell from 11‑14% in 2024 to flat in Q1 2026
- **Guidance outlook** (deteriorating): Guidance was raised in 2024, maintained in early 2025, then narrowed and lowered through 2025‑2026
- **Librela adoption** (deteriorating): Initially strong launch, later described as slower and declining before stabilizing
- **Competitive pressure** (deteriorating): Repeated mentions of new dermatology and parasiticide entrants and intensified competition
- **China headwinds** (resolved): Headwinds noted in 2024 calls but absent in later updates

## Guidance path

2024 Q2:raised → 2024 Q3:raised → 2024 Q4:maintained → 2025 Q1:vague → 2025 Q2:raised → 2025 Q3:vague → 2025 Q4:vague → 2026 Q1:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/ZTS`